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Abstract
To define the primary effects of aluminum on bone in the
mammalian species, we examined the dose/time-dependent
actions of aluminum in normal beagles. Administration of low
dose aluminum (0.75 mg/kg) significantly elevated the serum
aluminum (151.7±19.9 ,Ag/liter) compared with that in con-
trols (4.2±1.35 ,Ag/liter) but did not alter the calcium, creati-
nine, or parathyroid hormone. After 8 wk of therapy, bone
biopsies displayed reduced bone resorption (2.6±0.63 vs.
4.5±0.39%) and osteoblast covered bone surfaces (2.02±0.51
vs. 7.64±1.86%), which was indicative of low turnover. In con-
trast, prolonged treatment resulted in increased bone volume
and trabecular number (38.9±1.35 vs. 25.2±2.56% and
3.56±0.23 vs. 2.88±0.11/mm) which was consistent with un-
coupled bone formation.
Administration of higher doses of aluminum (1.20 mg/kg)
increased the serum aluminum further (1242.3±259.8 ,ug/liter)
but did not affect calcium, creatinine, or parathyroid hormone.
However, after 8 wk of treatment, bone biopsies displayed
changes similar to those after long-term, low-dose therapy. In
this regard, an increased trabecular number (3.41±0.18/mm)
and bone volume (36.5±2.38%) again provided evidence of un-
coupled bone formation. In contrast, in this instance poorly
mineralized woven bone contributed to the enhanced bone vol-
ume. High-dose treatment for 16 wk further enhanced bone
volume (50.4±4.61%) and trabecular number (3.90±0.5/mm).
These observations illustrate that aluminum may stimulate
uncoupled bone formation and induce a positive bone balance.
This enhancement of bone histogenesis contrasts with the ef-
fects of pharmacologic agents that alter the function of existing
bone remodeling units.
Introduction
Recent studies have identified aluminum as an agent which
can profoundly influence bone turnover (1-13). However, a
variety of discordant observations, as well as the complex clin-
ical circumstances in which aluminum effects have been ob-
served (10, 12, 14), have precluded establishing with certainty
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the primary effects of aluminum on bone. We designed the
present study in order to examine the dose/time-dependent
effects of aluminum administration on bone histology in the
normal beagle, an animal model which displays dynamic bone
remodeling similar to that in man. Our data indicate that alu-
minum treatment induces de novo bone histogenesis, an un-
precedented pharmacologic event.
Methods
Study protocol. 18 2-yr-old male beagles, weighing - 15 kg, were ran-
domly divided into three groups. During the study all animals were
housed under identical conditions in standard kennel runs and were
fed a normal diet containing 1.2% calcium, 0.6% phosphorus, and
2,200 U/kg (of diet) vitamin D3 (Purina Lab Chow, Ralston-Purina
Co., St. Louis, MO). The vitamin D supplementation maintained nor-
mal 25 hydroxyvitamin D levels in each group throughout the study
(69.1±4.5, 65.2±4.7, and 57.7±19.2 ng/ml, respectively). The group 1
dogs received 0.75 mg elemental aluminum/kg as aluminum chloride
intravenously three times per week for 16 wk while we administered a
higher dose ofaluminum, 1.20 mg/kg, to group 2 beagles over a similar
period. At the end of 8 and 16 wk of study, we biopsied the bones of
dogs from both groups 1 and 2. In addition, at similar time intervals we
obtained plasma for measurement of total and ionized calcium, phos-
phorus, creatinine, PTH, alkaline phosphatase, and aluminum. We
employed bone biopsies and plasma measurements from age-matched
beagles treated with pH-matched sodium chloride (as vehicle) (group
3) as normative values for comparison in these studies.
Biochemical studies. Plasma calcium, phosphorus, creatinine, and
alkaline phosphatase were measured by colorimetric techniques using
an autoanalyzer (Technicon Instruments Corp., Tarrytown, NY). The
ionized calcium concentration was determined using an ICA 1 analyzer
(Radiometer Inc., Copenhagen, Denmark), and values were corrected
to a pH of 7.4.
We measured the plasma PTH concentration using a radioimmu-
noassay kit (Nichols Laboratory, San Juan Capistrano, CA) designed
to measure the amino-terminal portion of the molecule according to
previously described methods (15). We validated assay sensitivity by
demonstrating that the PTH concentration in beagles (24.2±2.2
ng/ml) decreased significantly after parathyroidectomy (12±2.0
ng/ml), and increased upon induction ofvitamin D deficiency (71±2.0
ng/ml).
We assayed the plasma aluminum concentration according to pre-
viously described methods (16) using a flameless atomic absorption
spectrophotometer (Perkin-Elmer Corp., Instrument Div., Norwalk,
CT) with a graphite furnace. Interference was minimized by using a
diluent containing ammonium hydroxide. During periods of alumi-
num chloride treatment, plasma was obtained for assay 24 h after
intravenous administration of the drug.
Bone studies. After 8 and 16 wk ofstudy transcortical bone biopsies
were obtained alternately from the left and right anterior iliac crest of
group 1 and 2 dogs under general anesthesia. In order to minimize
variability due to variation ofthe biopsy site, we reproducibly procured
the bone samples from an area - 8 mm from the anterior iliac crest.
We administered tetracycline HCL (15 mg/kg i.v.) to each dog over a
48 h period from day 21 to day 19 before biopsy and Calcein (15 mg/kg
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Table I. Plasma Biochemistries in Control and Aluminum-treated Beagles
Low dose aluminum High dose aluminum











































Data were compared by one-way ANOVA and Tukey's multiple range test. Values that do not share a common superscript are significantly
different at P < 0.05. * Values represent mean±SEM.
i.v.) from day 6 to day 4 before biopsy. Bone specimens were fixed in
ethanol and embedded in methyl methacrylate, unstained or pre-
stained by the methods of Villanueva (17). 20- and 5-ym sections from
the iliac crest specimens were prepared for histomorphological exami-
nation according to previously published methods (14). Staining for
aluminum was performed on 5-gm prestained and unstained sections
by a modification of methods reported by Maloney et al. (18). Bone
aluminum content was measured as previously described ( 14).
Histomorphometric analysis of both static and dynamic parame-
ters of trabecular bone remodeling was performed utilizing a semiau-
tomated system (Osteoplan, Carl Zeiss Inc., Thomwood, NY) as de-
tailed elsewhere ( 19). Supplemental analysis was accomplished as nec-
essary by using an integrated reticle (Merz-Schenk, Wild, Heerbrugg,
Switzerland) (20). The following histologic functions were quantitated:
(a) trabecular bone volume (Th.BV/TV), the percentage ofthe sample
composed of trabecular bone; (b) relative lamellar osteoid volume
(LOV/BV), the percentage of trabecular bone volume composed of
unmineralized lamellar bone; (c) woven osteoid volume (WOV/BV),
the percentage of the trabecular bone volume consisting of woven
osteoid; (d) fractional osteoid surface (OS/BS), the percentage of the
trabecular bone surface covered by osteoid; (e) mean osteoid seam
width (MOSW); (f) resorptive surface (RS/BS), the percentage of
nonosteoid covered trabecular bone surface on which Howship's la-
cunae are present; (g) osteoblastic surface (Ob.S/BS), the percentage of
trabecular bone surface on which osteoblast-covered osteoid is present;
(h) osteoblastic index (OBI), the number of osteoblasts per 10 cm of
bone surface; (i) volume ofmarrow fibrosis (Fib/TV), the percentage of
fibrosis per total tissue volume; (j) mineral apposition rate (MAR)',
the average interlabel distance divided by the days elapsed between the
administration of the fluorescent labels; (k) labeled fraction of osteoid
(MS/OS), referred to as mineralization front and defined as the per-
centage ofosteoid-covered trabecular bone surface exhibiting a fluores-
cent second label with a minimum width of 3 gin; (1) labeled fraction
of trabecular bone (MS/BS), referred to as mineralizing surface and
defined as the percentage of mineralized bone surface exhibiting a
fluorescent second label with a minimum width of 3 gm; and (m)
aluminum surface (Al/BS), the percentage of trabecular bone surface
bearing aluminum stain. In addition, we calculated the following
functions according to previously published methods: (a) corrected
mineral apposition rate (cMAR), the rate of mineral apposition aver-
aged throughout the lifespan of the osteoid seams ( 14); (b) mineraliza-
tion lag time (MLT), a measure ofthe time (in days) during the lifespan
of an osteoid moiety when mineralization is not occurring (14); (c)
1. Abbreviations used in this paper: BFR/TV, tissue based mineralized
bone formation rate; MAR, mineral apposition rate; cMAR, corrected
MAR; MLT, mineralization lag time; MS/OS, labeled fraction of os-
teoid.
tissue based mineralized bone formation rate (BFR/TV), the volume
ofmineralized bone formed per year (14); and (d) the mean trabecular
number (Tb.N), a derived index related to bone volume by the follow-
ing formula: bone volume = mean trabecular thickness X mean tra-
becular number (21).
Statistical analysis. Results are expressed as the mean±SEM. Sta-
tistical evaluation for differences between groups was done using one-
way analysis of variance with a posteriori testing by the Tukey multi-
ple comparison procedure. We chose this approach after preliminary
evaluation of the data employing two-factor analysis of variance (alu-
minum dose and duration of therapy) revealed important interactions
between the factors for many ofthe dependent variables studied. Since
the presence of such significant interaction prevents meaningful inter-
pretation about the independent factors and allows conclusions about
combinations of dose and duration only, use of one-way analysis of
variance with each combination of dose and duration classified as a
separate treatment results in statistical data identical to those obtained
after two-way analysis ofvariance with a posteriori testing ofimportant
interactions (22). All computations were performed with the Stat-
graphics software package (Statistical Graphics Corp., Inc., Princeton,
NJ) employing an IBM PC-AT computer.
Materials. The authentic 1,25 dihydroxyvitamin D3 (1,25[OH12D3)
used in the assay for this metabolite was a gift from Dr. Milan Usko-
kovic, Hoffmann-La Roche, Inc. (Nutley, NJ). [3H]1,25(OH)2D3 (90
Ci/mmol) was purchased from Amersham Corp. (Arlington Heights,
IL). Adult beagles were obtained from Hazelton Research Animals
Corp. (Cumberland, VA).
Results
Low dose aluminum. Administration of aluminum at a rela-
tively low dose resulted in a significant elevation (P < 0.001) of
the serum aluminum concentration in treated beagles
(15 1.7±19.9 ug/liter) compared with that in controls
(4.2±1.35 ,ug/liter), but did not significantly alter the serum
total and ionized calcium, creatinine, immunoactive PTH, or
alkaline phosphatase after 8 or 16 wk of treatment (Table I).
However, the serum phosphorus concentration declined sig-
nificantly at each interval. The serum calcitriol levels tended to
increase but the levels were not significantly different from
those of controls (Table I).
Quantitative histomorphologic analysis of bone biopsies
revealed unique abnormalities after both 8 and 16 wk of treat-
ment. At the earlier time, representative sections from the
biopsies of treated dogs (Tables II and III) displayed a reduc-
tion of bone resorption and osteoblast-covered bone surfaces,
changes characteristic of a low turnover state. In addition,
















Table II. Static Indices of Trabecular Bone in Control and Aluminum-treated Beagles
Low dose aluminum High dose aluminum
Control
Trabecular bone volume (Th.BV/TV) (%)
Trabecular number (TB.N/mm)
Lamellar osteoid volume (LOV/BV) (%)
Woven osteoid volume (WOV/BV) (%)
Osteoid surface (OS/BS) (%)
Mean osteoid seam width (MOSW) (,gm)
Osteoblastic surface (Ob.S/BS) (%)
Resorptive surface (RS/BS) (% )
Osteoblast index (OBI) (No./10 cm)
Aluminum surface (AL/BS) (%)
Bone aluminum content (,g/g)
































































Data were compared by one-way ANOVA and Tukey's multiple range test. Values that do not share a common superscript are significantly
different at P < 0.05. * Values represent mean±SEM.
defective mineralization, evidenced by a decreased MS/OS,
occurred in association with the reduced osteoblast popula-
tion. However, maintenance of osteoid surface and volume, as
well as seam width, in spite ofdiminished tetracycline labeling,
indicated that a proportional inhibition of osteoid synthesis
had occurred. Commensurate with these changes was that the
mineralized bone formation rate significantly decreased. The
alterations of bone histology developed in accord with a sub-
stantial increment of the bone aluminum content compared
with that of controls (Table II). Moreover, histological staining
revealed that the diminished bone turnover developed in asso-
ciation with aluminum covering 9.3±2.8% of the bone sur-
faces.
Surprisingly, the continued administration of aluminum
for up to 16 wk produced alterations of bone histology which
sharply contrasted with those evidenced at 8 wk. Biopsies from
treated dogs displayed evidence of de novo bone formation
marked by buds of new lamellar bone appearing at previously
inactive surfaces (Fig. 1) and arborization of trabeculae (Fig.
2). Consistent with these observations was a significant in-
crease of bone volume and trabecular number compared with
that in biopsies of controls. These changes occurred in concert
with restoration of the osteoblast population, improvement of
bone resorptive activity, and early evidence of peritrabecular
fibrosis (Table II). Similar to specimens from 8 wk, however,
16-wk biopsies displayed a persistence of excessive inactive
osteoid, maintaining a diminished MS/OS. However, BFR/
TV was not decreased (Table III) since the total bone surface
exhibiting mineralization remained normal. These histological
changes were associated with a further increment of bone alu-
minum content and bone surface aluminum compared with
those in 8-wk-treated animals and controls (Table II).
High dose aluminum. Administration of the higher dose of
aluminum increased the serum aluminum concentration
(1,242.3+259.8 yg/liter) to a level significantly greater (P
< 0.001) than that in controls, as well as dogs treated with a
lower dose (P < 0.001). However, high dose treatment for 8
and 16 wk, similar to the low dose regimen, did not result in an
alteration of serum total and ionized calcium, alkaline phos-
phatase, calcitriol, or immunoactive PTH, but did signifi-
cantly decrease the serum phosphorus. In addition, beagles
receiving high dose therapy for 16 wk experienced a modest,
but significant, elevation of serum creatinine levels (Table I).
After 8 wk of treatment bone biopsies displayed changes
similar to those evidenced after 16 wk of low dose therapy. In
this regard, a more abundant arborization of trabecular bone
and consequent increased trabecular number and bone vol-
ume again provided evidence of enhanced de novo bone for-
mation (Fig. 3, Table II). In this instance, however, poorly
mineralized woven bone (osteoid) constituted the majority of
the newly synthesized tissue, comprising 11.5±4.6% of the
bone volume (Fig. 4). Deposition of tetracycline in wide bands
at the woven osteoid bone interface and as broad isolated foci
marked the abnormal mineralization within this tissue (Table
III). Consistent with this, the cMAR was decreased while esti-
mates ofMLT revealed increased values (Table III). The pres-
ence of woven bone and a coincident increase in the number
of osteoblasts within the tissue (Table II) indicate that an accel-
erated rate of matrix synthesis underlies the new bone forma-
tion. Indeed, the concomitant appearance of marrow fibrosis
provides further evidence that aluminum stimulation of mes-
enchymal cell proliferation (and differentiation) is responsible
for the observed changes. In any case, aluminum had no effect
on lamellar osteoid since this tissue persisted in normal
Figure 1. Microscopic appearance of bone obtained from a beagle
treated with low-dose aluminum for 16 wk. (Top) Villanueva-stained
specimen showing protuberances of bone projecting beyond the nor-
mal trabecular contour. Blue-stained osteoid covers these "buds" of
bone. (Bottom) Same section viewed under polarized light demon-
strates that the excrescences of bone maintain a lamellar structure. In
addition, the cement line (arrow) is unscalloped, suggesting uncou-
pled bone formation. X 200.





Table III. Dynamic Indices of Trabecular Bone in Control and Aluminum-treated Beagles
Low dose aluminum High dose aluminum
Control 8 wk 16 wk 8 wk 16 wk
Mineral apposition rate [MAR] (Mgm/d) 0.69±0.08a 0.82±0.12a 0.97±0.16a 0.92±0.08a 1.03±0.14a
Corrected mineral apposition rate [cMAR] (tLm/d) 0.50±0.06b 0.42±0.06b 0.44±0.07b 0.17±0.04a 0. 16±0.09a
Mineralization lag time [MLT] (d) 21.1±2.9a 26.6±3.8ab 30.8±4.2b 289.0±113.1c 204.4±65.4c
Mineralization front [MS/OS] (%) 71.9±2.92c 51.9±5.6b 46.0±4.2b 15.3±3.Oa 14.6±6.3a
Mineralizing surface [MS/BS] (% ) 8.9±1.1b 5.7±0.8a 6.7+0.7ab 5.3±1.5a 3.9±1.2a
Bone formation rate [BFR/TV] (%/yr) 16.3±1.58b 9.2±1.56a 18.8+6.75b 10.7±2.53a 6.6±4.01a
Data were compared by one-way ANOVA and Tukey's multiple range test. Values that do not share a common superscript are significantly
different at P < 0.05. * Values represent mean±SEM.
amounts (Table II). These complex alterations occurred in
association with a concomitant reduction in active bone re-
sorption and an increase of the bone aluminum content and
aluminum-covered bone surface (Table II).
Continuation of high-dose aluminum treatment for up to
16 wk resulted in further de novo bone formation. In this
regard, bone volume continued to increase as did the trabecu-
lar number (Table II). In contrast, while mineralization re-
mained abnormal, the presence of diminished woven osteoid
indicated that heterogeneous calcification of this tissue was
more complete (Fig. 5, Table III). Thus, the proportion of
mineralized bone that is woven significantly increased above
that evidenced after 8 wk of therapy (1.5±0.7 vs. 7.6±1.7%).
Discussion
Pharmacological induction of a positive bone balance remains
the goal of therapy in a variety of osteopenic disorders. How-
ever, in general, bone formation in the adult human skeleton
serves a replacement function, occurring only at locations
where bone resorption has been recently completed. Thus,
drug development efforts have been limited and have resulted
in selection of agents that alter the relationship between bone
resorption and formation in order to effect a change in bone
volume. In contrast, drugs that directly evoke the histogenesis
of new bone (without a preceding resorptive stage) have not
been identified.
The data in this study illustrate, however, that aluminum
administration stimulates uncoupled bone formation and in-
duction of a positive bone balance in adult beagles that exhibit
bone remodeling dynamics similar to those found in man.
Several observations support this conclusion. First, bone biop-
sies that display an increased bone volume concurrently man-
ifest normal or diminished resorptive activity. Second, long-
term, low-dose aluminum treatment results in the appearance
oflocalized excrescences ofmineralized bone over unscalloped
cement lines, consistent with de novo bone formation (23).
Third, at higher doses aluminum stimulates deposition of
woven bone over the majority of the trabecular envelope and,
most notably, in the marrow space. And finally, an increased
number of trabeculae, as well as enhanced bone volume,
marks the new bone formation. This apparent stimulation of
bone histogenesis contrasts with the effects of other pharmaco-
logical agents that solely alter function ofexisting bone remod-
eling units (24).
The mechanism(s) underlying the aluminum-mediated en-
hancement ofbone formation remain unknown. However, the
effects depend on variations of exposure time and/or dose.
Treatment with low-dose aluminum for 8 wk paradoxically
results in histological changes (Tables II and III) similar to
those observed in disorders that exhibit low bone turnover
(13). In contrast, longer term treatment or therapy with higher
doses causes a graded stimulation of cellular activity and new
bone formation (Tables II and III). These observations suggest
that aluminum may exert both inhibitory and stimulatory ef-
fects on osteoblasts. Indeed, a similar aluminum-induced bi-
phasic response of osteoblasts in vitro has been observed (25).
Whether the divergent activities in vivo represent direct ac-
tions or are mediated by hormonal/metabolic influences can-
not be determined from this study. While a decreased serum
phosphorus concentration did occur in all groups, the magni-
tude of the changes was uniformly similar, making it unlikely
that such a constant alteration evoked disparate histomorpho-
metric findings. Thus, it appears likely that the stimulatory
effects constitute a compensatory response to an initial inhibi-
tion of osteoblast function.
In any case, the positive effects of aluminum on osteoid
synthesis are undoubtedly mediated by an increase in both the
number and activity of osteoblasts. In this regard, the en-
hanced bone volume observed after 16 wk of low-dose treat-
ment occurred concomitantly with restoration of the depleted
osteoblast pool, while high-dose therapy resulted in an overt
increase in the number of osteoblasts (Table II). Moreover,
deposition of woven osteoid by the osteoblasts after treatment
with higher doses ofaluminum is itself indicative of enhanced
cellular activity (23) and is very similar to the rapid bone
proliferative response which occurs during fracture healing. In
addition, the concurrence of peritrabecular fibrosis and in-
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Figure 2. Microscopic appearance of a 5-pm-thick Goldner-stained histologic section of bone obtained from a beagle treated with low-dose alu-
minum for 16 wk (top) compared with that of a normal beagle (bottom). Mineralized trabecular bone from the dog receiving aluminum is
marked by "arborization" within the marrow space, reflecting the continuum of this proliferative response. x 100.

Figure 4. Villanueva-stained 5-Mm-thick section of bone after 8 wk of high-dose aluminum treatment. Plump osteoblasts (arrows) are seen both
upon the trabecular surface and within blue-stained woven osteoid. X 400.
creased bone volume provides further evidence that an in-
crease in the number and activity of osteoblasts mediates the
positive effects of aluminum (Table II). In this regard, alumi-
num most likely stimulates proliferation (and differentiation)
of a mesenchymal precursor which results in enhanced pro-
duction and activity of both fibroblasts and osteoblasts. Sev-
eral in vitro studies support this possibility. Data from these
investigations indicate that aluminum can directly stimulate
proliferation of both fibroblasts (26) and osteoblasts (25).
The apparent increase in osteoblast activity was incom-
plete. While enhanced cellular function resulted in synthesis
and secretion ofwoven osteoid (Figs. 3 and 4), mineralization
of the tissue (an apparent osteoblast-mediated event) was ab-
normal (Table III). Indeed, after 8 wk of high-dose treatment,
little calcification was evident. Although the mineralization
defect persisted with further therapy, at 16 wk heterogeneous
calcification of the vast majority of the woven tissue became
evident (Fig. 5). Whether the increased rate of bone synthesis
contributed to the mineralization defect or the abnormal cal-
cification resulted solely from an unrelated aluminum effect
remains unknown. In any case, the defective mineralization
and the enhanced rate of osteoid synthesis resulted in an in-
creased mean osteoid seam width (Table II). Moreover, the
existence of abnormal calcification prohibits estimating the
rate of osteoid synthesis by calculation of the BFR/TV. Con-
sequently, an increased BFR/TV does not mark the de novo
bone formation that occurred after high dose aluminum treat-
ment (Table III).
In addition, we did not observe an enhanced BFR/TV after
16 wk of low-dose therapy, in spite of apparent adequate min-
eralization (Table III). This aberration may be due to at least
two factors. These are (a) completion ofbone forming activity
before the biopsy, or (b) formation of new bone at sites that
have not been previously resorbed (uncoupling) combined
with a reduction in the remodeling space due to the concomi-
tant decrease of bone resorption. Indeed, the unscalloped ce-
Figure 3. Histologic findings in bone after 8 wk of high-dose alumi-
num therapy. (Top) Low power view of a 5-Mm-thick Goldner-
stained section reveals widespread deposition ofbrown staining os-
teoid over the trabecular envelope and within the marrow space
(arrows). X 40. (Bottom) High power view of a 5-um-thick Goldner-
stained section under polarized light illustrates that the newly depos-
ited osteoid has a woven structure. X 200.
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ment lines and excrescences of bone are consistent with the
latter interpretation. While we cannot discriminate between
these possibilities, the evidence of new bone formation re-
mains abundantly clear.
Both prostaglandin E2 and fluoride induce histologic
changes in bone similar in some respects to those observed in
the aluminum-treated beagles (27, 28). High-dose fluoride
treatment induces production of poorly mineralized woven
bone in excessive amounts (27). However, new tissue deposits
not only on endosteal surfaces, as we observed after aluminum
therapy, but on periosteal surfaces as well. Moreover, the en-
hanced bone formation follows increased resorption (29).
Consequently, the increase in bone mass occurs secondary to
thickening of existing trabeculae and not to production ofnew
units (30). A similar disparity likely exists between prostaglan-
din E2 and aluminum effects. However, studies of the prosta-
glandin have been performed in rodent models that do not
exhibit bone remodeling similar to that found in the beagle
(28, 31). Thus, comparisons are difficult. Nevertheless, the
exceptional effect of aluminum to stimulate bone formation
without increasing resorption remains uniquely different from
that of both prostaglandin E2 and fluoride (both of which en-
hance resorption) (29, 32).
In contrast to our studies, considerable clinical and epide-
miological evidence indicates that aluminum may be a patho-
genetic factor underlying the development of various bone
diseases which have as their hallmark abnormal mineraliza-
tion and decreased bone resorption and formation (1-7, 13).
However, attempts to produce animal model systems that ex-
hibit such aluminum-mediated osseous abnormalities have
provided conflicting data (8-12, 14). Experimental aluminum
exposure in normal animals has resulted in no discernable
bone pathology (14) or induction of diverse abnormalities
ranging from defective mineralization (consistent with osteo-
malacia) (8, 9, 11) and decreased bone formation (33) to stim-
ulation of resorption (12) and mineral apposition rate (10),
changes indicative ofincreased bone turnover. However, these
studies have been confounded by several factors. First, the
doses ofaluminum employed have often been large (exceeding
5 mg/kg per d), which may predispose to nonspecific toxicity
(9). Indeed, exposure has been terminated abruptly in several
studies due to a high attrition rate (9). Moreover, aluminum-
treated animals have frequently exhibited significant weight
loss due to poor intake of food and inadvertent nephrotoxicity
(8, 9, 11). Second, aluminum treatment has generally been
short, precluding evaluation of longer-term effects (8, 12).
Third, use of large doses of aluminum has resulted in liver
toxicity, causing a decrease of 25 hydroxyvitamin D levels
which may complicate interpretation of bone histomorpho-
metric changes (33, 34). And finally, the majority of studies
have used rodents as the animal models (8-10, 12). Because
the bone in these animals only undergoes modeling (31), their
bone physiology is fundamentally different from that in adult
dogs and humans. This difference may result in varying re-
sponses to aluminum. In any case, the histologic abnormalities
which have been observed in these animal models are similar,
but, in general, not entirely comparable, to the pathologic find-
ings attributed to aluminum in man (6). In our study we ad-
ministered aluminum intermittently and observed abnormal
bone mineralization dynamics and inhibition of bone resorp-
tion, changes similar to those reported in some animal studies
and found in man with aluminum-associated bone disease.
More importantly, we coincidentally noted de novo synthesis
ofwoven osteoid, which results in an increase in bone volume
and in trabecular number and represents a unique aluminum-
related effect that has not been previously reported. While we
cannot determine with certainty the cause for these discrepan-
cies, it appears likely that the aluminum-related osteodystro-
phies ofman and aluminum-induced bone diseases previously
reported in animal models occur secondary to the interaction
of aluminum with a permuted metabolic milieu. This milieu
may encompass uremia, among other abnormalities.
Regardless, the interrupted administration ofaluminum to
an animal model with dynamic bone remodeling and an un-
compromised metabolic state, as described in this paper, pro-
duces de novo bone formation. Although many questions re-
main about the mechanisms ofaction, potential marrow toxic-
ity (secondary to peritrabecular fibrosis), bone strength,
remodeling of woven bone, and the ability to sustain the in-
creased volume, aluminum appears to be a pharmacologic
agent which can increase osteoblast number, stimulate osteo-
blastic collagen synthesis, and thereby induce bone histogen-
esis in spite of inhibiting mineralization. As such, aluminum
may serve as a model to develop potential effective therapies
for the osteopenic disorders.
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